Literature DB >> 9571999

Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology.

J Müller-Quernheim1.   

Abstract

Immunopathogenic mechanisms in sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary manifestations of collagen-vascular diseases maintain an alveolitis which may lead to irreversible organ damage. The classical parameters used in the management of pulmonary involvement of these disorders are chest X-ray and pulmonary function test which do not gauge alveolitis but rather pulmonary impairment. From the immunopathogenesis several serological parameters have been delineated estimating different aspects of inflammatory processes. Cytokines, soluble cytokine receptors, metabolites, enzymes, extracellular matrix components, soluble adhesion molecules, and other serum components have been evaluated to serve as serological markers of alveolitis. The mechanisms gauged by these markers, and their clinical usefulness are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9571999

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  10 in total

1.  Sarcoidosis as a risk factor for venous thromboembolism.

Authors:  Anna Goljan Geremek; Witold Tomkowski; Marcin Geremek; Elżbieta Puścińska; Grzegorz Małek; Adam Nowiński; Michal Bednarek; Paweł Śliwiński
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Oral Lesion as the first Clinical Presentation in Sarcoidosis: A Case Report.

Authors:  Abdul Rahman S Al-Azri; Richard M Logan; Alastair N Goss
Journal:  Oman Med J       Date:  2012-05

3.  Sarcoidosis presenting as isolated gingival enlargement: a rare case entity.

Authors:  Pragya Tripathi; Jaihans Aggarwal; Deepak Chopra; Sukhchain Bagga; Kanika Sethi
Journal:  J Clin Diagn Res       Date:  2014-11-20

4.  Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia.

Authors:  Hideki Futamatsu; Jun-ichi Suzuki; Susumu Adachi; Hiroyuki Okada; Kenichiro Otomo; Takahiro Ohara; Yuji Hashimoto; Tsunekazu Kakuta; Yoshito Iesaka; Hiroaki Yamaguchi; Harumizu Sakurada; Akira Sato; Tohru Obayashi; Akihiro Niwa; Kenzo Hirao; Mitsuaki Isobe
Journal:  Int J Cardiovasc Imaging       Date:  2006-03-14       Impact factor: 2.357

Review 5.  Clinical and immunologic components of sarcoidosis.

Authors:  Andrea T Borchers; Calvin So; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

6.  Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis.

Authors:  M Sekiya; A Ohwada; K Miura; S Takahashi; Y Fukuchi
Journal:  Lung       Date:  2003       Impact factor: 2.584

7.  18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.

Authors:  Ruth G Keijsers; Fred J Verzijlbergen; Wim J Oyen; Jules M van den Bosch; Henk J Ruven; Heleen van Velzen-Blad; Jan C Grutters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

Review 8.  Serum biomarkers in interstitial lung diseases.

Authors:  Argyris Tzouvelekis; George Kouliatsis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-07-21

Review 9.  Venous thromboembolism and sarcoidosis: co-incidence or coexistence?

Authors:  Anna Goljan-Geremek; Marcin Geremek; Elzbieta Puscinska; Pawel Sliwinski
Journal:  Cent Eur J Immunol       Date:  2016-01-15       Impact factor: 2.085

10.  Verifying Sarcoidosis Activity: Chitotriosidase versus ACE in Sarcoidosis - a Case-control Study.

Authors:  Spasoje Popević; Zorica Šumarac; Dragana Jovanović; Dragan Babić; Mihailo Stjepanović; Snežana Jovičić; Dragana Šobić-Šaranović; Snežana Filipović; Branko Gvozdenović; Maja Omčikus; Anđela Milovanović; Jelica Videnović-Ivanov; Ana Radović; Vladimir Žugić; Violeta Mihailović-Vučinić
Journal:  J Med Biochem       Date:  2016-11-02       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.